Abstract
ABSTRACTMyeloid malignancies exhibit considerable heterogeneity with overlapping clinical and genetic features among different subtypes. Current classification schemes, predominantly based on clinical features, fall short of capturing the complex genomic landscapes of these malignancies. Here, we present a data-driven approach that integrates mutational features and clinical covariates within networks of their probabilistic relationships, enabling the discovery of de novo cancer subgroups. In a cohort of 1323 patients across acute myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia and myeloproliferative neoplasms, we identified novel subgroups that outperform established risk classifications in prognostic accuracy. Our findings suggest that mutational patterns are often shared across different types of myeloid malignancies, with distinct subtypes potentially representing evolutionary stages en route to leukemia. Within the novel subgroups, our integrative method discerns unique patterns combining genomic and clinical features to provide a comprehensive view of the multifaceted genomic and clinical landscape of myeloid malignancies. This in turn may guide the development of targeted therapeutic strategies and offers a pathway to enhanced patient stratification.
Publisher
Cold Spring Harbor Laboratory
Reference50 articles.
1. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms;Leukemia,2021
2. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia;Blood cancer journal,2022
3. Chronic myelomonocytic leukemia diagnosis and management;Leukemia,2021
4. International consensus classification of myeloid neoplasms and acute leukemias: integrating morpho-logic, clinical, and genomic data;Blood, The J. Am. Soc. Hematol,2022
5. The world health organization (WHO) classification of the myeloid neoplasms;Blood, The J. Am. Soc. Hematol,2002